<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.hqlo.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Health and Quality of Life Outcomes - Latest Articles</title>
        <link>http://www.hqlo.com</link>
        <description>The latest research articles published by Health and Quality of Life Outcomes</description>
        <dc:date>2009-07-03T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/61" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/60" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/59" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/58" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/57" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/56" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/55" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/54" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/53" />
                                <rdf:li rdf:resource="http://www.hqlo.com/content/7/1/52" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.hqlo.com/content/7/1/61">
        <title>Quality of life in Brazilian obese adolescents: effects of a long-term multidisciplinary lifestyle therapy</title>
        <description>Background:
Obesity has adverse physical, social, and economic consequences that can negatively affect quality of life (QOL). Thus the aim of this study was to verify the effects of a long-term multidisciplinary lifestyle intervention on QOL, body image, anxiety, depression and binge eating in obese adolescents.
Methods:
Sixty-six obese adolescents (41 girls and 25 boys; BMI: 35.62+/-4.18kg/m2) were recruited from the Multidisciplinary Obesity Intervention Program outpatient clinic, and were submitted to a multidisciplinary lifestyle therapy (short-term = 12 weeks and long-term = 24 weeks), composed of medical, dietary, exercise and psychological programs. Validated self-report questionnaires were used to assess symptoms of anxiety Trait/State (STAI); depression (BDI); binge eating (BES), body image dissatisfaction (BSQ) and QOL (SF-36). Data were analyzed by means of scores; comparisons were made by ANOVA for repeated measures, and Tukey&apos;s test as post-hoc and Students T test.
Results:
Long-term therapy decreased depression and binge eating symptoms, body image dissatisfaction, and improved QOL in girls, whereas, for boys, 24 weeks, were effective to reduce anxiety trait/state and symptoms of binge eating, and to improve means of dimensions of QOL (p&lt;.05).
Conclusions:
A long-term multidisciplinary lifestyle therapy is effective to control psychological aspects and to improve QOL in obese adolescents.</description>
        <link>http://www.hqlo.com/content/7/1/61</link>
                <dc:creator>Mara Cristina Lofrano-Prado</dc:creator>
                <dc:creator>Hanna Karen Moreira Antunes</dc:creator>
                <dc:creator>Wagner Luiz do Prado</dc:creator>
                <dc:creator>Aline de Piano</dc:creator>
                <dc:creator>Danielle Arisa Caranti</dc:creator>
                <dc:creator>Lian Tock</dc:creator>
                <dc:creator>June Carnier</dc:creator>
                <dc:creator>Sergio Tufik</dc:creator>
                <dc:creator>Marco Tulio de Mello</dc:creator>
                <dc:creator>Ana Damaso</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:61</dc:source>
        <dc:date>2009-07-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-61</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>61</prism:startingPage>
        <prism:publicationDate>2009-07-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/60">
        <title>Impact of gastroesophageal reflux disease on patients&apos; daily lives: a European observational study in the primary care setting</title>
        <description>Background:
The impact of gastroesophageal reflux disease (GERD) on the daily lives of patients managed in primary care is not well known. We report the burden of GERD in a large population of patients managed in primary care, in terms of symptoms and impact on patients&apos; daily lives.
Methods:
RANGE (Retrospective ANalysis of GERD) was an observational study that was conducted at 134 primary care sites across six European countries. All adult subjects who had consulted their primary care physician (PCP) during a 4-month identification period were screened retrospectively and those consulting at least once for GERD-related reasons were identified. From this population, a random sample of patients was selected to enter the study and attended a follow-up appointment, during which the Reflux Disease Questionnaire (RDQ), the GERD Impact Scale (GIS) and an extra-esophageal symptoms questionnaire were self-administered. Based on medical records, data were collected on demographics, history of GERD, its diagnostic work-up and therapy.
Results:
Over the 4-month identification period, 373,610 subjects consulted their PCP and 12,815 (3.4%) did so for GERD-related reasons. From 2678 patients interviewed (approximately 75% of whom reported taking medication for GERD symptoms), symptom recurrence following a period of remission was the most common reason for consultation (35%). At the follow-up visit, with regard to RDQ items (score range 0-5, where high score = worse status), mean Heartburn dimension scores ranged from 0.8 (Sweden) to 1.2 (UK) and mean Regurgitation dimension scores ranged from 1.0 (Norway) to 1.4 (Germany). Mean overall GIS scores (range 1-4, where low score = worse status) ranged from 3.3 (Germany) to 3.5 (Spain). With regard to extra-esophageal symptoms, sleep disturbance was common in all countries in terms of both frequency and intensity.
Conclusion:
In this large European observational study, GERD was associated with a substantial impact on the daily lives of affected individuals managed in the primary care setting.</description>
        <link>http://www.hqlo.com/content/7/1/60</link>
                <dc:creator>Javier Gisbert</dc:creator>
                <dc:creator>Alun Cooper</dc:creator>
                <dc:creator>Dimitrios Karagiannis</dc:creator>
                <dc:creator>Jan Hatlebakk</dc:creator>
                <dc:creator>Lars Agreus</dc:creator>
                <dc:creator>Helmut Jablonowski</dc:creator>
                <dc:creator>Javier Zapardiel</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:60</dc:source>
        <dc:date>2009-07-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-60</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>60</prism:startingPage>
        <prism:publicationDate>2009-07-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/59">
        <title>Reliability and validity of a new scale on internal coherence (ICS) of cancer patients</title>
        <description>Background:
Current inventories on quality of life used in oncology mainly focus on functional aspects of patients in the context of disease adaption and treatments (side) effects (EORTC QLQ C30) or generically the status of common functions (Medical Outcome Study SF 36). Beyond circumscribed dimensions of quality of life (i.e., physical, emotional, social, cognitive etc.), there is a lack of inventories which also address other relevant dimensions such as the `sense of coherence&apos; (SOC) in cancer patients. SOC is important because of its potential prognostic relevance in cancer patients, but the current SOC scale has mainly been validated for psychiatric and psychosomatic patients. Our two-step validation study addresses the internal coherence (ICS) scale, which is based on expert rating, using specific items for oncological patients, with respect to its reliability, validity and sensitivity to chemotherapy.
Methods:
The items were tested on 114 participants (57 cancer patients and a matched control group), alongside questions on autonomic regulation (aR), the Hospital Anxiety and Depression Scale (HADS), self-regulation (SRQ) and the Karnofsky Performance-Index (KPI). A retest of 65 participants was carried out after a median time span of four weeks.In the second part of the study, the ICS was used to assess internal coherence during chemotherapy in 25 patients with colorectal carcinoma (CRC) and 17 breast cancer patients. ICS was recorded before, during and 4 - 8 weeks after treatment.
Results:
The 10-item scale of `internal coherence&apos; (ICS) shows good to very good reliability: Cronbach-alpha r= 0.91, retest-reliability r= 0.80. The ICS correlates with r= 0.43 - 0.72 to the convergence criteria (all p&lt;0.001). We were able to show decreased ICS values after the third cycle for CRC and breast cancer patients, with a subsequent increase of ICS scores after the end of chemotherapy.
Conclusions:
The ICS has good to very good reliability, validity and sensitivity to chemotherapy.</description>
        <link>http://www.hqlo.com/content/7/1/59</link>
                <dc:creator>Matthias Kroz</dc:creator>
                <dc:creator>Arndt Bussing</dc:creator>
                <dc:creator>Hans Broder von Laue</dc:creator>
                <dc:creator>Marcus Reif</dc:creator>
                <dc:creator>Gene Feder</dc:creator>
                <dc:creator>Friedemann Schad</dc:creator>
                <dc:creator>Matthias Girke</dc:creator>
                <dc:creator>Harald Matthes</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:59</dc:source>
        <dc:date>2009-06-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-59</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>59</prism:startingPage>
        <prism:publicationDate>2009-06-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/58">
        <title>Rasch analysis of the Multiple Sclerosis Impact Scale (MSIS-29)</title>
        <description>Background:
Multiple Sclerosis (MS) is a degenerative neurological disease that causes impairments, including spasticity, pain, fatigue, and bladder dysfunction, which negatively impact on quality of life. The Multiple Sclerosis Impact Scale (MSIS-29) is a disease-specific health-related quality of life (HRQoL) instrument, developed using the patient&apos;s perspective on disease impact. It consists of two subscales assessing the physical (MSIS-29-PHYS) and psychological (MSIS-29-PSYCH) impact of MS. Although previous studies have found support for the psychometric properties of the MSIS-29 using traditional methods of scale evaluation, the scale has not been subjected to a detailed Rasch analysis. Therefore, the objective of this study was to use Rasch analysis to assess the internal validity of the scale, and its response format, item fit, targeting, internal consistency and dimensionality.
Methods:
Ninety-two persons with definite MS residing in the community were recruited from a tertiary hospital database. Patients completed the MSIS-29 as part of a larger study. Rasch analysis was undertaken to assess the psychometric properties of the MSIS-29.
Results:
Rasch analysis showed overall support for the psychometric properties of the two MSIS-29 subscales, however it was necessary to reduce the response format of the MSIS-29-PHYS to a 3-point response scale. Both subscales were unidimensional, had good internal consistency, and were free from item bias for sex and age. Dimensionality testing indicated it was not appropriate to combine the two subscales to form a total MSIS score.
Conclusions:
In this first study to use Rasch analysis to fully assess the psychometric properties of the MSIS-29 support was found for the two subscales but not for the use of the total scale. Further use of Rasch analysis on the MSIS-29 in larger and broader samples is recommended to confirm these findings.</description>
        <link>http://www.hqlo.com/content/7/1/58</link>
                <dc:creator>Melina Ramp</dc:creator>
                <dc:creator>Fary Khan</dc:creator>
                <dc:creator>RoseAnne Misajon</dc:creator>
                <dc:creator>Julie Pallant</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:58</dc:source>
        <dc:date>2009-06-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-58</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>58</prism:startingPage>
        <prism:publicationDate>2009-06-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/57">
        <title>Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches </title>
        <description>Background:
Missing data is classified as missing completely at random (MCAR), missing at random (MAR) or missing not at random (MNAR).  Knowing the mechanism is useful in identifying the most appropriate analysis. The first aim was to compare different methods for identifying this missing data mechanism to determine if they gave consistent conclusions.  Secondly, to investigate whether the reminder-response data can be utilised to help identify the missing data mechanism.
Methods:
Five clinical trial datasets that employed a reminder system at follow-up were used.  Some quality of life questionnaires were initially missing, but later recovered through reminders.  Four methods of determining the missing data mechanism were applied.  Two response data scenarios were considered.  Firstly, immediate data only; secondly, all observed responses (including reminder-response).
Results:
In three of five trials the hypothesis tests found evidence against the MCAR assumption. Logistic regression suggested MAR, but was able to use the reminder-collected data to highlight potential MNAR data in two trials.
Conclusions:
The four methods were consistent in determining the missingness mechanism.  One hypothesis test was preferred as it is applicable with intermittent missingness.  Some inconsistencies between the two data scenarios were found. Ignoring the reminder data could potentially give a distorted view of the missingness mechanism.  Utilising reminder data allowed the possibility of MNAR to be considered.</description>
        <link>http://www.hqlo.com/content/7/1/57</link>
                <dc:creator>Shona Fielding</dc:creator>
                <dc:creator>Peter Fayers</dc:creator>
                <dc:creator>Craig Ramsay</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:57</dc:source>
        <dc:date>2009-06-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-57</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>57</prism:startingPage>
        <prism:publicationDate>2009-06-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/56">
        <title>Development and preliminary evaluation of a quality of life measure targeted at dementia caregivers</title>
        <description>Background:
Providing care for individuals with a progressive, debilitating condition such as dementia can adversely impact the quality of life (QOL) of informal caregivers. To date, there is no existing caregiver quality of life measure for dementia caregivers with breadth of coverage or that is applicable to caregivers of diverse ethnic backgrounds. The purpose of this study was to develop and evaluate a caregiver-targeted quality-of-life measure (CGQOL) for informal caregivers of persons with dementia that can be used with caregivers from a variety of ethnicities.
Methods:
91 items were field tested by telephone interviews with 179 English-speaking and 21 monolingual Spanish-speaking caregivers of persons with dementia.  Repeat interviews were conducted with 71 caregivers.  Administration time, scale score distributions, item-scale correlations, reliability, and associations of scales with patient and caregiver demographic and caregiving characteristics were estimated.  Structure of associations among scales was examined using exploratory factor analysis.
Results:
Item analysis yielded 80 items distributed across 10 scales, with median administration time of 17 minutes (IQR 13.5-22 minutes) and minimal missing data.  There were few floor or ceiling effects in scale score distributions.  Internal consistency reliability was &gt; 0.78 for all scales; test-retest reliability (intraclass correlation) estimates exceeded 0.70 for 6 scales.  More hours weekly spent in caregiving was uniquely associated with worse quality of life on 8 scales (p&apos;s &lt;0.05).  Three higher-order dimensions of caregiving assistance, emotional and social concerns, and spirituality and benefits were identified.
Conclusions:
These preliminary results support subsequent evaluation of test-retest reliability, construct validity, and responsiveness to change of this quality-of-life measure for caregivers from diverse ethnicities.</description>
        <link>http://www.hqlo.com/content/7/1/56</link>
                <dc:creator>Barbara Vickrey</dc:creator>
                <dc:creator>Ron Hays</dc:creator>
                <dc:creator>Michele Maines</dc:creator>
                <dc:creator>Stefanie Vassar</dc:creator>
                <dc:creator>Jaime Fitten</dc:creator>
                <dc:creator>Tony Strickland</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:56</dc:source>
        <dc:date>2009-06-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-56</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>56</prism:startingPage>
        <prism:publicationDate>2009-06-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/55">
        <title>The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms</title>
        <description>Background:
The purpose of the current study was to validate the US English Patient Perception of Study Medication (PPSM) questionnaire, which measures patient satisfaction with Benign Prostatic Hyperplasia (BPH) treatment and was administered to men with BPH lower urinary tract symptoms (LUTS) enrolled in a multi-national clinical trial.
Methods:
Patients with moderate to severe BPH symptoms completed three disease-specific measures: The International Prostate Symptom Score (IPSS), the BPH Impact Index (BII) and the PPSM, at baseline (after completion of the placebo run-in period) and at every 13-week clinic visit thereafter for the duration of the study treatment period. The PPSM was analysed to assess its variability, reliability and validity.
Results:
There were 879 patients included in the analyses, with a mean age of 66.7 years. The PPSM was found to comprise two factors - PPSM-Global and PPSM-Pain, with a Total Score ranging from 7 to 49. It demonstrated good internal consistency (Cronbach&apos;s alpha ranged from .95 to .97) and also demonstrated convergent validity through significant correlations with the IPSS (.48 to .58), IPSS Quality of Life (QoL) item (.41 to .63) and BII (.31 to .45) and known-groups validity against the IPSS, IPSS QoL item and BII.
Conclusion:
Results support the use of the PPSM as a measure of satisfaction in BPH patient groups.</description>
        <link>http://www.hqlo.com/content/7/1/55</link>
                <dc:creator>Libby Black</dc:creator>
                <dc:creator>Alyson Grove</dc:creator>
                <dc:creator>Betsy Morrill</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:55</dc:source>
        <dc:date>2009-06-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-55</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>55</prism:startingPage>
        <prism:publicationDate>2009-06-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/54">
        <title>Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgia</title>
        <description>Background:
Sleep disturbances are a common and bothersome symptom of fibromyalgia (FM). This study reports psychometric properties of a single-item scale to assess sleep quality among individuals with FM.
Methods:
Analyses were based on data from two randomized, double-blind, placebo-controlled trials of pregabalin (studies 1056 and 1077).  In a daily diary, patients reported the quality of their sleep on a numeric rating scale ranging from 0 (&quot;best possible sleep&quot;) to 10 (&quot;worst possible sleep&quot;).  Test re-test reliability of the Sleep Quality Scale was evaluated by computing intraclass correlation coefficients.  Pearson correlation coefficients were computed between baseline Sleep Quality scores and baseline pain diary and Medical Outcomes Study (MOS) Sleep scores.  Responsiveness to treatment was evaluated by standardized effect sizes computed as the difference between least squares mean changes in Sleep Quality scores in the pregabalin and placebo groups divided by the standard deviation of Sleep Quality scores across all patients at baseline.
Results:
Studies 1056 and 1077 included 748 and 745 patients, respectively.  Most patients were female (study 1056: 94.4%; study 1077: 94.5%) and white (study 1056: 90.2%; study 1077: 91.0%).  Mean ages were 48.8 years (study 1056) and 50.1 years (study 1077).  Test re-test reliability coefficients of the Sleep Quality Scale were 0.91 and 0.90 in the 1056 and 1077 studies, respectively.  Pearson correlation coefficients between baseline Sleep Quality scores and baseline pain diary scores were 0.64 (p&lt;0.001) and 0.58 (p&lt;0.001) in the 1056 and 1077 studies, respectively.  Correlations between the Sleep Quality Scale and the MOS Sleep subscales were statistically significant (p&lt;0.01), except for the MOS Snoring subscale.  Across both studies, standardized effect sizes were generally moderate (0.46 to 0.52) for the 300 mg group and moderate (0.59) or moderate-to-large (0.70) for the 450 mg group.  In study 1056, the effect size for the 600 mg group was moderate-to-large (0.73).  In study 1077, the effect size for the 600 mg group was large (0.82).
Conclusions:
These results provide evidence of the reproducibility, convergent validity, and responsiveness to treatment of the Sleep Quality Scale and provide a foundation for its further use and evaluation in FM patients.</description>
        <link>http://www.hqlo.com/content/7/1/54</link>
                <dc:creator>Joseph Cappelleri</dc:creator>
                <dc:creator>Andrew Bushmakin</dc:creator>
                <dc:creator>Anne McDermott</dc:creator>
                <dc:creator>Alesia Sadosky</dc:creator>
                <dc:creator>Charles Petrie</dc:creator>
                <dc:creator>Susan Martin</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:54</dc:source>
        <dc:date>2009-06-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-54</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>54</prism:startingPage>
        <prism:publicationDate>2009-06-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/53">
        <title>One-year health-related quality of life outcomes in weight loss trial participants: comparison of three measures</title>
        <description>Background:
The literature on changes in health-related quality of life (HRQOL) in weight loss studies is inconsistent, and few studies use more than one type of measure. The purpose of the current study was to compare one-year changes in HRQOL as a function of weight change using three different measures: a weight-related measure (Impact of Weight on Quality of Life-Lite [IWQOL-Lite)]) and two generic measures (SF-36; EQ-5D).
Methods:
Data were obtained from 926 participants (mean Body Mass Index (BMI) (kg/m2) = 35.4; 84% female; mean age = 49.5 years) in a placebo-controlled randomized trial for weight loss. At baseline and one-year, participants completed all three HRQOL measures. HRQOL was compared across weight change categories (&#8805; 5% and 0&#8211;4.9% gain, 0&#8211;4.9%, 5.0&#8211;9.9% and &#8805; 10% loss), using effect sizes.
Results:
The weight-related measure of HRQOL exhibited greater improvements with one-year weight loss than either of the generic instruments, with effect sizes ranging from 0.24 to 0.62 for 5&#8211;9.9% weight reductions and 0.44 to 0.95 for &#8805; 10% reductions. IWQOL-Lite Self-Esteem also showed a small improvement with weight gain. Changes in the two generic measures of HRQOL were inconsistent with each other, and in the case of the SF-36, variable across domains. For participants gaining &#8805; 5% of weight, the greatest reductions in HRQOL occurred with respect to SF-36 Mental Health, MCS, and Vitality, with effect sizes of -0.82, -0.70, and -0.63 respectively.
Conclusion:
This study found differences between weight-related and generic measures of health-related quality of life in a one-year weight loss trial, reflecting the potential value of using more than one measure in a trial. Although weight loss was generally associated with improved IWQOL-Lite, physical SF-36 subscale and EQ-5D scores, a small amount of weight gain was associated with a slight improvement on weight-specific HRQOL and almost no change on the EQ-5D, suggesting the need for further research to more fully study these relationships. We believe our findings have relevance for weight loss patients and obesity clinicians/researchers in informing them of likely HRQOL outcomes associated with varying amounts of weight loss or gain.</description>
        <link>http://www.hqlo.com/content/7/1/53</link>
                <dc:creator>Ronette Kolotkin</dc:creator>
                <dc:creator>Josephine Norquist</dc:creator>
                <dc:creator>Ross Crosby</dc:creator>
                <dc:creator>Shailaja Suryawanshi</dc:creator>
                <dc:creator>Pedro Teixeira</dc:creator>
                <dc:creator>Steven Heymsfield</dc:creator>
                <dc:creator>Ngozi Erondu</dc:creator>
                <dc:creator>Allison Nguyen</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:53</dc:source>
        <dc:date>2009-06-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-53</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>53</prism:startingPage>
        <prism:publicationDate>2009-06-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.hqlo.com/content/7/1/52">
        <title>Health-related Quality of Life of Southern Chinese with Chronic Hepatitis B infection</title>
        <description>Background:
Few studies have evaluated the health-related quality of life (HRQOL) of Southern Chinese with chronic hepatitis B (CHB) infection.AimTo evaluate the HRQOL of Chinese patients at different stages of CHB infection and to find out factors associated with HRQOL.
Methods:
520 Chinese adult CHB patients of whom 156 were uncomplicated, 102 had impaired liver function, 139 had cirrhosis and 123 had hepatocellular carcinoma (HCC) were interviewed with a structured questionnaire, the SF-36 Health Survey version 2 (SF-36v2), and the Chronic Liver Disease Questionnaire (CLDQ). The differences in SF-6D health preference values and SF-36v2 scores between each CHB group and Hong Kong population norms were assessed by t-test. ANOVA was used to compare the mean SF-6D health preference, SF-36v2 scores, and CLDQ scores among CHB groups. Multiple linear regressions were performed to identify determinants of HRQOL.
Results:
CHB patients had significantly lower SF-36v2 scores than the population norm. The SF-6D values of CHB patients with uncomplicated disease, impaired liver function, HCC and cirrhosis were 0.755, 0.745, 0.720 and 0.701, respectively, all significantly lower than the population norm of 0.787. Advanced stage of CHB illness, anti-viral treatment, bilirubin level, psychological co-morbidity, younger age and female were associated with poorer HRQOL.
Conclusion:
CHB infection had a negative impact on HRQOL. There was a progressive decrease in health preference values with CHB disease progression. The results can be used for the estimation of quality adjusted life years (QALYs) for CHB patients in cost effectiveness or cost utility studies.Trial Registrationhttp://www.hkclinicaltrials.com; HKCTR-151.</description>
        <link>http://www.hqlo.com/content/7/1/52</link>
                <dc:creator>Elegance TP Lam</dc:creator>
                <dc:creator>Cindy LK Lam</dc:creator>
                <dc:creator>Cl Lai</dc:creator>
                <dc:creator>Mf Yuen</dc:creator>
                <dc:creator>Daniel YT Fong</dc:creator>
                <dc:creator>Thomas MK So</dc:creator>
                <dc:source>Health and Quality of Life Outcomes 2009, 7:52</dc:source>
        <dc:date>2009-06-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7525-7-52</dc:identifier>
        <prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName>
        <prism:issn>1477-7525</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>52</prism:startingPage>
        <prism:publicationDate>2009-06-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
